A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz438.022
Abstract: Abstract Background Hepatocellular carcinoma (HCC) is the most common malignancy with high rates of recurrence and metastasis after radical resection. Vascular invasion, including portal vein tumor thrombus (PVTT) and microvascular invasion (MVI), and microsatellite lesions… read more here.
Keywords: apatinib; recurrence; shr 1210; therapy ... See more keywords
Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
Sign Up to like & getrecommendations! Published in 2021 at "BMC Oral Health"
DOI: 10.1186/s12903-021-01901-9
Abstract: Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and… read more here.
Keywords: capillary hemangiomas; reactive capillary; shr 1210; treatment ... See more keywords
Safety and efficacy of GVD and anti-PD-1 (SHR-1210) regimen with or without low-dose decitabine priming for refractory bulky and aggressive primary mediastinal large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7556
Abstract: 7556Background: Relapsed/refractory PMBCL (rrPMBCL) generally has limited treatment options and dismal prognosis. Recently, monotherapy of anti-PD-1 was reported to induce an effective and durable ... read more here.
Keywords: shr 1210; anti shr; efficacy gvd; safety efficacy ... See more keywords
Biomarker exploration for SHR-1210 plus GEMOX as first-line treatment in advanced biliary tract cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.536
Abstract: 536Background: We conducted a trial to evaluate the efficacy and safety of SHR-1210 (a humanized anti-programmed cell death receptor 1 antibody) plus gemcitabine and oxaliplatin (GEMOX) as in untre... read more here.
Keywords: plus gemox; shr 1210; 1210 plus; exploration shr ... See more keywords